CSIMarket
 


Tenx Keane Acquisition  (TENKU)
Other Ticker:  
 
 

TENKU's Net Income Growth by Quarter and Year

Tenx Keane Acquisition's Net Income results by quarter and year




TENKU Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 1.03 0.00 0.00
III Quarter September - 0.16 0.00 0.00
II Quarter June - 0.62 0.00 0.00
I Quarter March 0.49 0.61 0.00 0.00
FY   0.49 2.42 0.00 0.00



TENKU Net Income first quarter 2024 Y/Y Growth Comment
Tenx Keane Acquisition reported decline in Net Income in the first quarter 2024 by -19.7% to $ 0.49 millions, from the same quarter in 2023.
The contraction in the first quarter 2024 Tenx Keane Acquisition's Net Income compares unfavorably to the Company's average Net Income no change of 0%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Net Income growth. While Tenx Keane Acquisition' s Net Income fall of -19.7% ranks overall at the positon no. 1047 in the first quarter 2024.




TENKU Net Income ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March -19.7 % - - -
FY   - - - -

Financial Statements
Tenx Keane Acquisition's first quarter 2024 Net Income $ 0.49 millions TENKU's Income Statement
Tenx Keane Acquisition's first quarter 2023 Net Income $ 0.61 millions Quarterly TENKU's Income Statement
New: More TENKU's historic Net Income Growth >>


TENKU Net Income (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 543.75 % - -
III Quarter September - -74.19 % - -
II Quarter June - 1.64 % - -
I Quarter March -52.44 % - - -
FY (Year on Year)   - - - -




Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #17
Healthcare Sector #74
Overall #1047

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #17
Healthcare Sector #74
Overall #1047
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Tenx Keane Acquisition's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
554.25 % 107.01 % -74.37 %
(Dec 31 2023)  


TENKU's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2024 Tenx Keane Acquisition reported fall in Net Income from the previous quarter by -52.44% to $ 0.49 millions, from $ 1.03 millions declared in the previous quarter.

Within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Net Income quarter on quarter growth. While Tenx Keane Acquisition's Net Income growth quarter on quarter, overall rank is 1428.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #100
Overall #1428
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #24
Healthcare Sector #100
Overall #1428
Net Income Q/Q Growth Statistics
High Average Low
554.25 % 107.01 % -74.37 %
(Dec 31 2023)  


TENKU's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2024 Tenx Keane Acquisition reported fall in Net Income sequentially by -52.44% to $ 0.49 millions, from $ 1.03 millions released a quarter before.

Within Major Pharmaceutical Preparations industry 23 other companies have achieved higher Net Income quarter on quarter growth. While Tenx Keane Acquisition's Net Income growth quarter on quarter, overall rank is 1428.


Tenx Keane Acquisition's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Net Income 12 Months Ending $ 2.30 $ 2.42 $ 0.00 $ 0.00 $ 0.00
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) -5.04 % - - - -
Seq. Net Income Growth (TTM) Overall Ranking # 1050 # 0 # 0 # 0 # 0




Cumulative Net Income growth Comment


Tenx Keane Acquisition achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 74
S&P 500 # 1050
Cumulative Net Income growth Comment


Tenx Keane Acquisition achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 74
S&P 500 # 1050




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
TENKU's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for TENKU's Competitors
Net Income Growth for Tenx Keane Acquisition's Suppliers
Net Income Growth for TENKU's Customers

You may also want to know
TENKU's Annual Growth Rates TENKU's Profitability Ratios TENKU's Asset Turnover Ratio TENKU's Dividend Growth
TENKU's Roe TENKU's Valuation Ratios TENKU's Financial Strength Ratios TENKU's Dividend Payout Ratio
TENKU's Roa TENKU's Inventory Turnover Ratio TENKU's Growth Rates TENKU's Dividend Comparisons



Companies with similar Net Income fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2024
Iqvia Holdings Inc -0.35%$ -0.346 millions
Cadre Holdings inc -1.06%$ -1.057 millions
Exelixis Inc -1.95%$ -1.950 millions
Quest Diagnostics Inc-4.15%$ -4.147 millions
Progyny Inc -4.41%$ -4.412 millions
3m Company-4.89%$ -4.893 millions
Mettler Toledo International Inc-5.79%$ -5.794 millions
Utah Medical Products Inc-6.12%$ -6.122 millions
Abbott Laboratories-7.06%$ -7.056 millions
Entera Bio Ltd -7.90%$ -7.900 millions
National Research Corporation-8.69%$ -8.688 millions
Regeneron Pharmaceuticals Inc -11.71%$ -11.714 millions
Baxter International Inc -13.33%$ -13.333 millions
Phibro Animal Health Corporation-16.30%$ -16.302 millions
West Pharmaceutical Services Inc -17.64%$ -17.643 millions
Atrion Corporation-19.89%$ -19.885 millions
Tenx Keane Acquisition-19.93%$ -19.927 millions
Catalyst Pharmaceuticals Inc -21.28%$ -21.283 millions
American Shared Hospital Services-35.00%$ -35.000 millions
Amedisys Inc-41.41%$ -41.411 millions
Dariohealth Corp -44.05%$ -44.055 millions
Fonar Corporation-44.64%$ -44.638 millions
Envista Holdings Corporation-46.12%$ -46.119 millions
Viatris Inc -49.31%$ -49.310 millions
Pro dex Inc -50.11%$ -50.114 millions
Avantor Inc -50.29%$ -50.288 millions
Ir med Inc -51.33%$ -51.333 millions
Privia Health Group Inc -52.26%$ -52.265 millions
Orgenesis Inc -57.20%$ -57.202 millions
Oramed Pharmaceuticals Inc -57.52%$ -57.519 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com